CHRONIC prurigo recommendations clarify diagnosis, severity assessment, and personalized treatment pathways for patients with persistent itch.
A Delphi consensus panel has outlined evidence-based recommendations for the diagnosis and management of chronic prurigo, a chronic neuroinflammatory skin disease marked by persistent pruritus, repeated scratching, and multiple pruritic skin lesions. The guidance aims to standardize clinical decision-making for a disease that can be difficult to recognize because of overlapping features with other dermatologic, systemic, neurologic, and psychiatric conditions.
The panel defined chronic prurigo diagnosis by the concomitant presence of pruritus lasting at least 6 weeks, a history or signs of repeated excoriation, and multiple localized or generalized pruritic lesions. These may include nodules, papules, umbilicated lesions, or linear lesions. Diagnosis should rely on patient history and physical examination, with laboratory tests or further investigations used when clinically indicated.
Chronic Prurigo Workup Should Assess Comorbidities
The recommendations emphasize a comprehensive clinical history, including itch duration, location, intensity, episodic or continuous pattern, triggers, relieving factors, and systemic symptoms such as night sweats, fever, weight loss, and fatigue. Physical examination should assess the full skin surface, including mucous membranes, scalp, nails, and anogenital region.
Initial laboratory evaluation for chronic prurigo should include complete blood count, blood glucose, creatinine, liver enzymes, inflammatory markers, thyroid-stimulating hormone, urinalysis, and other baseline tests. Viral serologies for HIV, hepatitis B virus, and hepatitis C virus also reached consensus. Depending on clinical findings, total serum IgE, chest X-ray, abdominal ultrasound, skin biopsy, or hypersensitivity testing may be considered.
Personalized Treatment Pathways Guide Chronic Prurigo Care
Treatment should be individualized according to disease severity, quality-of-life impact, psychological profile, comorbidities, and concomitant therapies. The panel recommended regular use of clinician- and patient-reported outcomes, including Investigator Global Assessment tools, Worst Itch Numeric Rating Scale, Sleep Disturbance Numeric Rating Scale, Prurigo Activity and Severity Score, Dermatology Life Quality Index, and Hospital Anxiety and Depression Scale.
Systemic options for eligible patients include chronic prurigo-approved biologic agents, specifically dupilumab and nemolizumab, as well as gabapentinoids and antidepressants. Additional options may include IL-13 inhibitors, Janus kinase inhibitors, opioid receptor modulators, methotrexate, and cyclosporine. Treatment efficacy should be reassessed regularly to document clinical improvement, guide adjustment, and support adherence. Together, the recommendations provide a practical framework for closing diagnostic and therapeutic gaps in chronic prurigo care.
Reference
Mendes-Bastos P et al. Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel. Dermatol Ther (Heidelb). 2026;doi:10.1007/s13555-026-01766-2.
Featured Image: patient doctor consultation on Adobe Stock.
